makers of semaglutide Drug maker Novo Nordisk has announced that its weight-loss drug failed to slow down the decline in memory and thinking in people with early Alzheimer's disease. This disappointing news will come Novo Nordisk's oral GLP-1 drug

Creatine supports muscle performance, water retention within muscle cells, and may help preserve lean mass during calorie restriction

These trials tested semaglutide for different uses, such as diabetes and obesity treatment

At the conclusion of the three studies, results were reported as follows: Average weight loss: 5.9% of starting weight among 3,122 participants across three studies

"Retatrutide vs CagriSema vs Survodutide: Three Next-Gen Weight Loss Drugs Compared" earns its keep when it helps a reader move from a broad question to a cleaner next step

Discard expired vials and use only unexpired medication

In this analysis, patients on the 7.2 mg dose lost an average of 18.8% of their body weight, compared with 15.5% for the 2.4 mg dose and 3.9% for placebo